This Biliary Tract Cancer (BTC)- Epidemiology Forecast-2032 report delivers an in-depth understanding of the Biliary Tract Cancer (BTC), historical and forecasted epidemiology as well as the Biliary Tract Cancer (BTC) trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Study Period: 2019-2032
Biliary tract cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin's tumor), and distal CCA. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found in the tissues of the gallbladder. It originates in the cells of the gallbladder and most are adenocarcinomas, which begin in the gland cells of the gallbladder lining. Cholangiocarcinoma is a type of cancer that develops within the bile duct system, which is a series of small tubes that transport bile fluid from the liver (where it is produced) to the gallbladder (where it is stored).
The signs and symptoms of Biliary Tract Cancer may include pruritus, abdominal pain, malaise, fatigue, jaundice, fever, and more. The majority of BTC cases develops in the absence of identifiable risk factors, as most cases are sporadic and have no identifiable risk factors. However, several conditions have been linked to carcinogenesis which can include primary sclerosing cholangitis, parasitic infections, intrahepatic biliary stones, Caroli's disease, and others.
For a definitive diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and several procedures named as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI, CT, endoscopic ultrasonography, or 18FDG PET-CT cannot definitively demonstrate the stricture's neoplastic nature.
Endoscopic ultrasonography-guided fine-needle aspiration demonstrated good diagnostic performance for discriminating benign versus malignant biliary strictures and without apparent risk of tumor seeding linked with the procedure. As for iCCA, the risk of tumor seeding after transperitoneal biopsy of pCCA is based on limited evidence. The role of FISH-polisomy in detecting CCA in patients with PSC has been questioned by a meta-analysis due to its limited sensitivity. Better markers are therefore required for early CCA detection. In this regard, serum CA19-9 levels can be helpful for the detection of CCA. However, the CA19-9 serum level is biased by elevation due to cholangitis and cholestasis and is undetectable in Lewis-antigen-negative patients.
The epidemiology section provides insights about the historical and current Biliary Tract Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total number of Biliary Tract Cancer cases was 37,451 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology [segmented as Total Incident Cases of BTC, Total age-specific cases of BTC, Total stage-specific cases of BTC, Total mutation-specific cases of BTC, and Total treated cases of BTC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Biliary Tract Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
To keep up with the current Biliary Tract Cancer patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Biliary Tract Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Biliary Tract Cancer Understanding
Biliary tract cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin's tumor), and distal CCA. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found in the tissues of the gallbladder. It originates in the cells of the gallbladder and most are adenocarcinomas, which begin in the gland cells of the gallbladder lining. Cholangiocarcinoma is a type of cancer that develops within the bile duct system, which is a series of small tubes that transport bile fluid from the liver (where it is produced) to the gallbladder (where it is stored).
The signs and symptoms of Biliary Tract Cancer may include pruritus, abdominal pain, malaise, fatigue, jaundice, fever, and more. The majority of BTC cases develops in the absence of identifiable risk factors, as most cases are sporadic and have no identifiable risk factors. However, several conditions have been linked to carcinogenesis which can include primary sclerosing cholangitis, parasitic infections, intrahepatic biliary stones, Caroli's disease, and others.
Diagnosis
For a definitive diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and several procedures named as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI, CT, endoscopic ultrasonography, or 18FDG PET-CT cannot definitively demonstrate the stricture's neoplastic nature.
Endoscopic ultrasonography-guided fine-needle aspiration demonstrated good diagnostic performance for discriminating benign versus malignant biliary strictures and without apparent risk of tumor seeding linked with the procedure. As for iCCA, the risk of tumor seeding after transperitoneal biopsy of pCCA is based on limited evidence. The role of FISH-polisomy in detecting CCA in patients with PSC has been questioned by a meta-analysis due to its limited sensitivity. Better markers are therefore required for early CCA detection. In this regard, serum CA19-9 levels can be helpful for the detection of CCA. However, the CA19-9 serum level is biased by elevation due to cholangitis and cholestasis and is undetectable in Lewis-antigen-negative patients.
Biliary Tract Cancer Epidemiology
The epidemiology section provides insights about the historical and current Biliary Tract Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total number of Biliary Tract Cancer cases was 37,451 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology [segmented as Total Incident Cases of BTC, Total age-specific cases of BTC, Total stage-specific cases of BTC, Total mutation-specific cases of BTC, and Total treated cases of BTC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Biliary Tract Cancer Epidemiology
The epidemiology segment also provides the Biliary Tract Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
KOL-Views
To keep up with the current Biliary Tract Cancer patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Biliary Tract Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report
- The report covers the descriptive overview of Biliary Tract Cancer, explaining their causes, symptoms, pathophysiology, and diagnosis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Biliary Tract Cancer.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Cancer, Total number of cancer cases at risk for Biliary Tract Cancer, Total number of Biliary Tract Cancer cases induced by cancer treatment, Total Severity-specific cases of Biliary Tract Cancer.
- Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Biliary Tract Cancer
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Biliary Tract Cancer Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Biliary Tract Cancer Epidemiology Segmentation
Key Questions Answered
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Biliary Tract Cancer?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Biliary Tract Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Biliary Tract Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Biliary Tract Cancer?
- Out of all 7MM countries, which country would have the highest incident population of Biliary Tract Cancer during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Biliary Tract Cancer Disease market
- To understand the future market competition in the Biliary Tract Cancer Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Biliary Tract Cancer Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Biliary Tract Cancer Disease market
- To understand the future market competition in the Biliary Tract Cancer Disease market
Table of Contents
1. Key Insights2. Report Introduction5. Epidemiology and Market Methodology10. Patient Journey11. Unmet Needs13. Publisher Capabilities14. Disclaimer15. About the Publisher
3. Biliary Tract Cancer (BTC) Market Overview at a Glance
4. Executive Summary of Biliary Tract Cancer (BTC)
6. Disease Background and Overview
8. Current Treatment Practices of Biliary Tract Cancer
9. Epidemiology and Patient Population
12. Appendix
List of Tables
List of Figures
